References
- Fox RI. Epidemiology, pathogenesis, animal models, and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1994; 6: 501–508
- Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, Guerrero D, Talal N, Dang H. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997; 40: 87–97
- Fujihara T, Fujita H, Tsubota K, Saito K, Tsuzaka K, Abe T, Takeuchi T. Preferential localization of CD8+ αEβ7+T cells around acinar epithelial cells with apoptosis in patients with Sjögren's syndrome. J Immunol 1999; 163: 2226–2235
- Schaffer A, Jacobsen A. Mikulicz's syndrome: a report of ten cases. Am J Dis Child 1927; 34: 327–346
- Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Mikulicz's disease and Sjögren's syndrome. Invest Ophthalmol Vis Sci 2000; 41: 1666–1673
- Tsubota K, Fujita H, Tadano K, Onoda N, Tsuzaka K, Takeuchi T. Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands. Clin Exp Immunol 2002; 129: 177–182
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–558
- Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: Gene structure, chromosomal location and species specificity. Int Immunol 1994; 6: 1567–1574
- Tsuzaka K, Nozaki K, Kumazawa C, Shiraishi K, Setoyama Y, Yoshimoto K, Suzuki K, Abe T, Takeuchi T. DNA microarray gene expression profile of T cells with the splice variants of TCRζ mRNA observed in SLE. J Immunol 2006; 176: 949–956
- Chen JY, Wang CM, Ma CC, Chow YH, Luo SF. The − 844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE. Genes Immun 2005; 6: 123–128
- Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP. A novel polymorphic CAAT/enhancer-binding protein element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003; 70: 132–138
- Fernandez RM, Noval JA, Garcia-Lozano JC, Borrego S, Molini JL, Antinolo G. Polymorphisms in the promoter regions of FAS and FASL genes as candidate genetic factors conferring susceptibility to endometriosis. Int J Mol Med 2005; 15: 865–869
- Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 2007; 27: 991–994
- Li C, Wu W, Liu J, Qian L, Li A, Yang K, Wei Q, Zhou J, Zhang Z. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: A case-control analysis. Pharmacogenet Genomics 2006; 16: 245–251
- Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y, Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42: 479–484
- Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM. Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 2001; 276: 4964–4971
- Kavurma MM, Bobryshev Y, Khachigian LM. Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1. J Biol Chem 2002; 277: 36244–36252
- Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347–1349
- Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935–946
- Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale–Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996; 335: 1643–1649
- Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, Fischer A. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996; 348: 719–723
- Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98: 1107–1113